MedTrace Logo

Effectiveness And Impact Of Nirsevimab In Chile (NIRSE-CL)

NCT06511687 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 160000

Last updated 2024-07-22

No results posted yet for this study

Summary

The Nirse-CL study is a collaborative effort between the Ministry of Health of Chile, Instituto Sistemas Complejos de Ingeniería (ISCI), and the Faculty of Medicine of the University of Chile. The primary aim is to determine the effectiveness of the monoclonal antibody nirsevimab in preventing RSV infection in infants based on the integrated analysis of several national databases before, during, and after the implementation of a universal immunization program. The impact of the program on RSV-related health outcomes will also be determined.

Conditions

Interventions

BIOLOGICAL

Nirsevimab

Nirsevimab will be administered in a single dose at birth for newborn cohort and at the beginning of the campaign for the other cohorts under study

Sponsors & Collaborators

  • Instituto Sistemas Complejos de Ingeniería

    lead OTHER

Eligibility

Max Age
4 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-04-01
Primary Completion
2024-10-01
Completion
2024-10-01
FDA Drug
Yes

Countries

  • Chile

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06511687 on ClinicalTrials.gov